BERKELEY, CA--(Marketwired - March 17, 2016) - Dynavax Technologies Corporation (
Date and Time: Monday, April 18, 2016, 1:00 p.m. - 5:00 p.m. EDT
Abstract Title: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial
Session Title: Phase I Clinical Trials 1
Abstract Control Number: 7361
Permanent Abstract Number: CT047
Location: Convention Center, Halls G-J, Poster Section 13
Poster Board Number: 3
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 18, 2016.
Date and Time: Monday, April 18, 2016, 1:00 p.m. - 5:00 p.m. EDT
Abstract Title: Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade
Session Title: Immune Checkpoints 1
Abstract Control Number: 4045
Permanent Abstract Number: 2322
Location: Convention Center, Halls G-J, Poster Section 26
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 18, 2016.
Date and Time: Wednesday April 20, 2016, 8:00 a.m. - 12:00 p.m. EDT
Abstract Title: Radiation potentiates systemic anti-tumor immunity unleashed by a novel TLR9 agonist (SD-101)
Session Title: Immune Modulation from Non-Immunotherapy and Antibodies: Clinical
Abstract Number: 4985
Location: Convention Center, Halls G-J, Poster Section 26
Poster Board Number: 9
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 20, 2016.
About SD-101
SD-101, the subject of AACR abstracts CT047, 2322 and 4985, is Dynavax's proprietary, second-generation, CpG-C class oligodeoxynucleotide TLR 9 agonist. SD-101 activates multiple anti-tumor mechanisms of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and induce high levels of Type I interferons and maturation of plasmacytoid dendritic cells and B cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.
Contact Information:
Contact:
Michael Ostrach
Chief Financial Officer
510-665-7257